Table 1 Baseline patient characteristics (n = 27) and association with cfDNA levels and detection of ctDNA.
From: Circulating DNA and frequency of colorectal cancer brain metastases in a presumed high-risk group
n (%)a | Total cfDNA level by DFA | ctDNA detection by ddPCR | ||||
|---|---|---|---|---|---|---|
ng/µl plasma | p-valueb | No | Yes | p-valuec | ||
Median (95% CI) | n (%) | n (%) | ||||
Age, median (range) | 67 (40–90) | |||||
< 67 years | 13 (48%) | 0.73 (0.58–1.08) | 0.55 | 6 (46%) | 7 (54%) | 0.71 |
≥ 67 years | 14 (52%) | 0.73 (0.60–0.89) | 8 (57%) | 6 (43%) | ||
Sex | ||||||
Female | 10 (37%) | 0.73 (0.58–0.97) | 0.71 | 5 (50%) | 5 (50%) | 1.00 |
Male | 17 (63%) | 0.78 (0.60–1.06) | 9 (53%) | 8 (47%) | ||
WHO performance status | ||||||
0 | 8 (30%) | 0.67 (0.50–0.94) | 0.74d | 6 (75%) | 2 (25%) | 0.62d |
1–2 | 9 (33%) | 0.75 (0.56–1.02) | 5 (56%) | 4 (44%) | ||
Missing | 10 (37%) | 0.85 (0.58–1.50) | 3 (30%) | 7 (70%) | ||
Primary tumor resected? | ||||||
Yes | 22 (81%) | 0.68 (0.60–0.82) | < 0.01 | 13 (59%) | 9 (41%) | 0.17 |
No | 5 (19%) | 1.10 (0.78–1.91e) | 1 (20%) | 4 (80%) | ||
Disease status | ||||||
No evidence of disease | 5 (19%) | 0.62 (0.35–1.04e) | 0.16f | 4 (75%) | 1 (25%) | 0.06 |
Stable disease | 10 (37%) | 0.73 (0.60–0.89) | 0.35f | 7 (70%) | 3 (30%) | |
Progressive disease | 12 (44%) | 0.81 (0.59–1.09) | 3 (25%) | 9 (75%) | ||
Number of metastatic sites | ||||||
0 | 5 (19%) | 0.62 (0.35–1.04e) | 0.35g | 4 (80%) | 1 (20%) | 0.02 |
1 | 7 (26%) | 0.86 (0.58–1.10) | 0.53g | 6 (86%) | 1 (14%) | |
≥ 2 | 15 (56%) | 0.75 (0.60–0.89) | 4 (27%) | 11 (73%) | ||
Liver metastases? | ||||||
No | 19 (70%) | 0.65 (0.59–0.91) | 0.12 | 12 (63%) | 7 (37%) | 0.10 |
Yes | 8 (30%) | 0.81 (0.67–1.77) | 2 (25%) | 6 (75%) | ||
Mutational status in tumor tissue | ||||||
Wild-type | 9 (33%) | 0.73 (0.56–1.06) | 0.78d | 5 (56%) | 4 (44%) | 1.00d |
Mutated | 14 (52%) | 0.69 (0.60–0.83) | 7 (50%) | 7 (50%) | ||
Missing | 4 (15%) | 0.91 (0.72–1.10e) | 2 (50%) | 2 (50%) | ||
